Bristol-Myers Squibb (BMY)

Bristol Myers Squibb is facing down a major patent cliff, which is a problem and a huge motivating force.

The S&P 500 (^GSPC) is often seen as a benchmark for strong businesses, but that doesn’t mean every stock is worth owning. Some companies face significant ch...

These healthcare leaders are unlikely to suspend their dividend programs.

IHE delivered 53.2% returns over one year with lower volatility and a 0.37% expense ratio, while PBE's quantitative biotech strategy carries higher risk.

As the Q2 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the pharmaceuticals industry, including Oc...

Earnings results often indicate what direction a company will take in the months ahead. With Q2 behind us, let’s have a look at Corcept (NASDAQ:CORT) and its...

Novo Nordisk, CVS Health, and Bristol Myers are top dividend stocks that are trading at modest valuations.

The stocks featured in this article have all approached their 52-week highs. When these price levels hit, it typically signals strong business execution, pos...

Companies try to get deals done while regulators allow them. But are buyouts always a good idea?

Bristol-Myers Squibb trades at less than half the valuation multiple of AbbVie, but AbbVie's revenue growth tells a different story about future earnings power.

There's a good reason why AstraZeneca tanked when merger rumors hit the Street.

This problem has a solution, and Pfizer is implementing it.

While profitability is essential, it doesn’t guarantee long-term success. Some companies that rest on their margins will lose ground as competition intensifi...

Bristol Myers Squibb’s second quarter results were marked by strong contributions from its growth portfolio, leading to a positive market reaction. Managemen...

Growth portfolio now drives 60% of revenue as Eliquis surges 21%.

Bristol Myers Squibb's P/E ratio is below the industry average, but you have to take this key fact into consideration before buying it.

Bristol Myers Squibb (NYSE:BMY) reported second-quarter 2026 revenue of approximately $13 billion, up 5% from a year earlier, as growth in newer products offset declines across its legacy portfolio. The company raised its full-year revenue and adjusted diluted earnings-per-share guidance, citing fir

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on ...

Growth portfolio now drives 60% of revenue as Eliquis surges 21%.

It notched convincing beats on analyst estimates with its second-quarter performance.

Things are going well for the pharmaceutical giant.

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) reported Q2 CY2026 results exceeding the market’s revenue expectations, with sales up 5.7% year on ...

Biopharmaceutical company Bristol Myers Squibb (NYSE:BMY) will be reporting results this Thursday before market open. Here’s what to look for. Bristol-Myers ...